Sionna Therapeutics (SION) Q2 2025 earnings summary

Executive summary

• Positive topline Phase 1 data for NBD1 stabilizers SION-719 and SION-451, both well tolerated and exceeding pharmacokinetic targets, supporting advancement to next-stage trials.

• Clinical-stage biopharma focused on novel cystic fibrosis therapies targeting CFTR's NBD1 domain, aiming to restore near-normal CFTR function.

• Phase 2a proof-of-concept trial for SION-719 and Phase 1 dual combination trial for SION-451 are on track for H2 2025, with topline data expected mid-2026.

• Completed IPO in February 2025, raising $199.6 million; all outstanding preferred stock converted to common stock.

• In-licensed three clinical-stage compounds from AbbVie in 2024 to expand combination therapy portfolio.

Financial highlights

• Net loss of $34.6 million for the six months ended June 30, 2025, compared to $20.4 million for the same period in 2024.

• Net loss widened to $18.1 million in Q2 2025 from $8.6 million in Q2 2024.

• Research and development expenses increased to $29.1 million for the six months ended June 30, 2025, and to $15.4 million in Q2 2025 from $8.2 million in Q2 2024.

• General and administrative expenses rose to $12.5 million for the six months ended June 30, 2025, and to $6.5 million in Q2 2025 from $3.1 million in Q2 2024.

• Cash, cash equivalents, and marketable securities totaled $337.3 million as of June 30, 2025.

Outlook and guidance

• Cash runway expected to fund operations into 2028 based on current plans.

• Topline data from ongoing and upcoming clinical trials anticipated in mid-2026.

• Anticipates increased expenses as clinical programs advance and pipeline expands.